Strong India, weak US; specialty launches stall despite clinical progress

Delivered result shows 10.5% YoY; transcript reports 10.1% (₹151,836M vs ₹15,299.9Cr baseline)

Delivered PAT ₹2,901.2 Cr (₹29,012M), 6.5% lower than transcript adjusted figure

Corroborated: branded generics and innovative medicines grew, offsetting Lenalidomide loss. Mix-driven expansion confirmed.

Stated in transcript; but global specialty revenue flat over last 3 quarters despite Leqselvi (6+ months) and Unloxcyt (launched Q4 FY26) launches. Growth % not contradicted but impact on overall revenue structure weak.

Delivered result ₹15,299.9Cr total; US ≈26.6% = ₹4,066Cr. Lenalidomide exit acknowledged, competitive pressure confirmed in Q&A (5 new launches, but base business soft).

Strong growth corroborated; volume growth 5.4% vs IPM 2%, new product launches (5), field expansion all visible. Market leadership position solid.

Slowdown acknowledged, but attribution vague. No specific country exposure disclosed. Risk understated.

Q1 at 5.4%; management invoked 'trial timing gap.' No visibility on which trials stopped/started. Variability unresolved.

Lenalidomide exit accelerated; competition in base products intensified. Prior ~15% US revenue base now in structural decline absent major new launches. Cash generation model impaired.

Leqselvi/Unloxcyt both >1,000 prescribers/positive access feedback, but consolidated specialty revenue flat 3Q. Ramp timeline extended vs typical specialty curve; suggests payer access, pricing, or substitution headwinds not fully disclosed.

Prior quarters 15–20%+ USD growth; Q1 4.2%. Geopolitical (Middle East) and macro cited, but no country-level disclosure. Suggests structural issues beyond macro noise.

16% growth, market share 8.2% → 8.5%, volume growth 5.4% vs IPM 2%. New products (5 launched), field expansion, brand building all supporting. Domestic engine remains core.

80.5% margin (higher YoY) via branded generics + innovative medicine share growth offsetting Lenalidomide exit. Adjusted EBITDA margins higher YoY when Lenalidomide-benefit removed. Quality improvement, but dependent on continued mix shift.

27.8% Q1 vs 24.3% Q1 FY26. India low-tax regime benefit exhausted; varying global rates now headwind. Expected to stay ~27.8% until Organon closes, then uncertain.

Rick cited Levulan seasonality (actinic keratosis, seasonal demand). Kirti declined product-wise guidance but said Ilumya, Unloxcyt, Leqselvi all expected to grow.

Jayashree: branded generics and innovative medicines both grew, improved overall mix. Share of revenue went up, margins reflected.

Dilip: time gap between stopping trials and starting new indication trials. Don't focus on Q1; will meet annual guidance. 70% on generics and India products.

Rick: Leqselvi has majority of covered lives; added important plan this quarter. Unloxcyt focused on cancer center/integrated delivery network formularies, progressing well due to differentiated mechanism.

Jayashree: two components—launch costs mostly behind us, but ongoing commercialization spend continues. Forex headwind also in expenses. R&D lower this Q, will normalize. Look at all three factors together.

Jayashree: stick to high single-digit. Mindful of FX headwinds across P&L. Current quarter positive, but uncertain how it translates rest of year.

Rick: Q-o-Q decline due to competition on few products and Levulan seasonality. Leqselvi/Unloxcyt contributing, will continue to grow. Won't provide product-wise targets.

Aalok: combination of geopolitical issues and difficult macroeconomic conditions in certain countries.

Dilip: many products registered for US also sold in other geographies. Creating basket of products to grow globally. (Avoided turnaround timeline.)

Dilip: Leqselvi has strong cytokine downregulation profile. Will prioritize and identify areas where can differentiate and register non-competitive. Both Leqselvi and Unloxcyt potential opportunities to expand indications. Rick: conducting investigator-initiated trials in US.

Rick: products early in growth curve, including Unloxcyt just launched months ago. Give it time. Other portfolio products showing strong growth. Seasonality on one product impacting rates.

Kirti: all business units doing well. Focus on new prescriptions, brand building, field force expansion in tier 2/3. Overall therapy areas performing. Volume growth 5.4% vs IPM 2%. 50% growth from volume+new products, 50% price.

Kirti: don't know what slowdown they refer to. Sun #2 among generics. Doing well on prescription and value side. Unique auto-injector format driving adoption. Excited about opportunity.

Aalok: premature to comment. Other generics may not get approval, making opportunity more attractive. Our focus is best possible launch.

Rick: don't provide product-wise guidance. Expect continued growth based on all indicators (access, prescriber base, repeat Rx). Similar differentiation for both, should grow at comparable pace.

Kirti: 50% from volume+new products, 50% from price. Volume growth 5.4% vs IPM 2%, well ahead of market.

Kirti: June particularly strong, but hard to pinpoint where growth coming from or if sustainable.

Jayashree: don't give stand-alone. Consol 27.8% due to India low-tax benefit exhaustion and varying jurisdiction rates. Expect range to continue until Organon closes. Will seek optimization but look at as range.

Abhishek: don't provide geographic breakup for innovative business.

Kirti: MM-II for orthopedic pain, knee joints—prescribed by orthopedicians/rheumatologists. Sun has no US commercial presence in this segment, so partnership makes sense.

Jayashree: three factors—(1) annual merit increase in Q1, (2) additional field force for two new launches not in prior year, (3) field force increases in other markets for innovative medicine promotion, (4) forex impact. Reality: merit increase, field force necessity, forex headwind, all valid.

Abhishek: ROW flat in dollar terms, but don't give forward guidance on specific region. Look at overall company revenue guidance.

Aalok: large majority branded generics; some pricing pressure, but not driving force.

Kirti: other new products (SGLT2 inhibitors, combinations) also launching. Diabetes incidence rising. Hard to forecast, but many new drivers entering market.

Jayashree: don't comment specifically. All costs factored into overall business case when in-licensing asset.

Rick: can't provide now; claims data lagged, always few months behind reality.

Rick: no supply issues; don't believe that data is accurate for Y-o-Y and Q-o-Q.

Kirti: yes, track IQVIA, AWACS, and agency data. #1 in 12 therapy areas per SMSRC.

Kirti: within normal bounds. Volume growth and new prescriptions 60% of total growth, 40% from volume, 20% new products. Indicates prescription growth.

Reiterated despite Q1 beat at 10.5%. Management explicitly held line: 'stick to high single-digit growth for full year,' mindful of FX headwinds across P&L.

ETR expected ~27.8% range until Organon closes; higher than prior 24.3% due to India tax benefit exhaustion. Gross margin expansion supported by mix; EBITDA margin slightly lower but adjusted higher YoY ex-Lenalidomide.

Q1 at 5.4%; Dilip cited trial timing gap, expects to meet annual guidance. Innovative R&D 30% of total spend. Variability in quarterly spend unresolved.

Leqselvi (Jun launch, >1,000 prescribers, strongest month) and Unloxcyt (positive feedback, formulary adds) both showing prescriber traction but consolidated specialty revenue flat 3 quarters. Suggests access, pricing, or cannibalization headwinds. Revenue ramp timeline extended vs typical specialty curve.

US business down 9.7% YoY; Lenalidomide exit primary driver, but 'additional competition in certain products' also cited. Turnaround timeline vague. Management avoided forecast; unlikely generics business returns to growth in FY27.

Emerging markets growth collapsed to 4.2% from 15–20%+ prior 2 quarters. Attributed to 'geopolitical issues and difficult macroeconomic conditions' but no country-level disclosure. Risk of structural competitive loss masked by macro excuse.

Adjusted PAT ₹30,894M vs delivered ₹29,012M (6.5% gap, ₹1,882M). Adjustments not transparent; suggests management may be optimistic on add-backs. Market may not accept same adjustment next quarter.

Organon acquisition expected close Q4 FY27 (~₹15–20Bn deal value estimated). ₹1,617M charges Q1, more 'back-ended with substantial part accrued at closing.' Integration complexity (combining two listed pharma companies, overlapping portfolios) high. Synergy realization timeline uncertain.

ETR 27.8% vs 24.3% Q1 FY26; India low-tax regime benefit exhausted. Varying rates across jurisdictions now headwind. Expected to hold ~27.8% until Organon closes; FY28+ trajectory uncertain.